Gastrinoma

Maria Duca speaking at the ELRIG Drug Discovery conference in London, UK. Credit: Frankie Fattorini/ GlobalData As interest mounts in using RNA as a therapeutic target, a group at the Institute of Chemistry in Nice is overcoming the need for lengthy, expensive screening of candidate compounds with a rational design approach. Dr. Maria Duca, head of the Targeting of Nucleic Acids team, outlined her team’s novel approach to RNA-targeting drug discovery, in a presentation today (3 October) at the ELRIG Drug Discovery 2024 conference in London, UK. Duca pointed out, “If we look at currently marketed drugs, these mainly target proteins, but these proteins represent a very small percentage of what the human genome encodes. If we take into account non-coding RNAs as potential targets for drugs, we could really widen the landscape of current medicinal chemistry.” However, according to Duca, “The problem is that you don’t have many rational design methodologies in order to design your compound specific for a particular RNA target. So, everything is mostly based on screenings.” Instead of mass screenings, Duca and her team assemble and test novel molecular conjugates to be target-specific and therapeutically effective. Duca said some of the more promising candidates created using this approach have potential in oncological and infectious disease indications. See Also: Advancing Pharmaceutical Security: The Role of SECURtracers in On-Dose Authentication Healthcare Payers for the Pharmaceutical Industry Duca outlined the discovery process behind her team’s conjugate against microRNA-327 (miRNA-327), an oncogenic RNA implicated in gastric cancer. The team conjugated the aminoglycoside neomycin with different artificial nuclear bases. The conjugates produced were screened in vitro for their selectivity and inhibitive activity towards miRNA-327. Promising candidates from these screens could then be studied in vivo. In gastrinoma cancer cells, which are characterised by miRNA-327 overexpression, the team found the chosen candidates inhibited cell proliferation in a dose-dependent manner. Imaging the conjugate-RNA interactions allowed them to further refine these neomycin conjugates for their miRNA-327 affinity and inhibition. Through this same process of design, in vitro screening, in vivo testing, and further structural refinement of conjugates, Duca and her team have produced therapeutic candidates targeting other RNAs. For example, they built another library of candidates targeted against miRNA-21 which is overexpressed in glioblastoma, a type of brain cancer. Applying the same rational design process, researchers produced candidates that inhibited glioblastoma cell proliferation, in a way that was comparable with the efficacy of temozolomide, one of the few palliative treatments for glioblastoma, marketed as Kimozo / Kizfizo by Orphelia Pharma. mRNA vaccine coverage on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Trilink . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper mRNA capping: low cost, high reward Are you aware of the latest mRNA capping techniques? The success of mRNA-based Covid vaccines has seen the technology boom in popularity – but capping is an essential part of the manufacturing process, and pharmaceutical firms face a range of choices on how to do it. This free whitepaper assesses differences in price, time, complexity and availability for the methods on offer – and provides essential insights on TriLink’s trailblazing CleanCap® approach. Fill in your details to find out more. Thank you. You will receive an email shortly. Please check your inbox to download the Whitepaper. By Trilink Thematic By downloading this Whitepaper, you acknowledge that GlobalData may share your information with Trilink Thematic and that your personal data will be used as described in their Privacy Policy

精彩内容 7月23日，NMPA官网显示，湖北津药药业的法莫替丁注射液通过仿制药一致性评价。法莫替丁是第三代H2受体拮抗剂，2023年中国公立医疗机构终端法莫替丁注射剂销售额超过27亿元，有望入选第十批集采。 法莫替丁是继西咪替丁和雷尼替丁后出现的又一种H2受体桔抗剂，具有对H2受体亲和力高的特点，对胃酸分泌有明显的抑制作用，对基础分泌及因给予各种刺激而引起的胃酸及胃蛋白酶增加有抑制作用。适用于消化性溃疡（胃、十二指肠溃疡），急性胃黏膜病变，反流性食管炎以及胃泌素瘤。 米内网数据显示，2023年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端法莫替丁注射剂销售额超过27亿元。其中，山西威奇达光明制药、江西赣南海欣药业、开封康诺药业3家企业的市场份额均超过10%。 中国公立医疗机构终端法莫替丁注射剂销售情况（单位：万元） 来源：米内网中国公立医疗机构药品终端竞争格局 国内已上市的法莫替丁注射剂有3种，包括注射用法莫替丁、法莫替丁注射液、法莫替丁氯化钠注射液。其中，注射用法莫替丁、法莫替丁氯化钠注射液尚未有企业过评；法莫替丁注射液已有8家企业过评，包括亚邦医药、辰欣药业、北京布霖生物、汇宇制药、湖北津药药业等，有望被纳入第十批集采。 湖北津药药业过评品种 来源：米内网一致性评价进度数据库 截至目前，湖北津药药业已有10款注射剂盐酸氨溴索注射液、胞磷胆碱钠注射液、吡拉西坦注射液、盐酸利多卡因注射液、甘油果糖氯化钠注射液、法莫替丁注射液、氟康唑氯化钠注射液、克林霉素磷酸酯注射液、呋塞米注射液、地塞米松磷酸钠注射液通过/视同通过仿制药一致性评价。 资料来源：米内网数据库、NMPA注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。 本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

精彩内容日前，国家药监局官网显示，辰欣药业、湖北神州华瑞医药的法莫替丁注射液同日通过一致性评价，目前该产品过评企业数已达5家，满足国采初步入围条件。米内网数据显示，2023年中国公立医疗机构终端法莫替丁注射剂销售额超过27亿元。法莫替丁属于组胺H2受体阻滞药，适用于消化性溃疡（胃、十二指肠溃疡），急性胃黏膜病变，反流性食管炎以及胃泌素瘤。在临床应用中，法莫替丁以注射剂为主。米内网数据米内显示，2022年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端法莫替丁注射剂销售额突破30亿元，2023年回落至超27亿元。近年来中国公立医疗机构终端法莫替丁注射剂销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局目前已有亚邦医药、北京布霖生物、华夏生生药业(北京)、辰欣药业、湖北神州华瑞医药5家企业的法莫替丁注射液过评或视同过评，已满足国采初步入围条件。此外，还有40余家企业的产品提交补充申请或以新分类报产在审，后续竞争激烈。法莫替丁注射剂过评情况来源：米内网一致性评价进度数据库截至目前，辰欣药业已有38个品种过评或视同过评，其中10个为血液和造血系统药物，消化系统及代谢药、全身用抗感染药物各有7个，神经系统药物有5个，心脑血管系统药物有4个等。辰欣药业已过评品种资料来源：米内网数据库、国家药监局官网等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至5月27日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦